Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

ANAVEX2-73 Study in Parkinson's Disease Dementia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03774459
Recruitment Status : Completed
First Posted : December 13, 2018
Last Update Posted : October 22, 2020
Sponsor:
Collaborator:
Anavex Germany GmbH
Information provided by (Responsible Party):
Anavex Life Sciences Corp.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients with Parkinson's Disease with Dementia (PDD)

Condition or disease Intervention/treatment Phase
Parkinsons Disease With Dementia Drug: High dose ANAVEX2-73 Drug: Mid dose ANAVEX2-73 Drug: Placebo oral capsule Phase 2

Detailed Description:
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, three-arm, 14-week study in PD patients with dementia. The study includes a 2 week Screening / Baseline Observation Period and a 14-week Treatment Period (including a 2 week Titration Period), and a 2-week Safety Follow-Up Period
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 132 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With Dementia
Actual Study Start Date : July 9, 2018
Actual Primary Completion Date : September 30, 2020
Actual Study Completion Date : September 30, 2020

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: High dose ANAVEX2-73
High dose ANAVEX2-73
 Drug: High dose ANAVEX2-73
Active oral capsule
Experimental: Mid dose ANAVEX2-73
Mid dose ANAVEX2-73
 Drug: Mid dose ANAVEX2-73
Active oral capsule
Placebo Comparator: Placebo oral capsule
Placebo oral capsule
 Drug: Placebo oral capsule
Placebo oral capsule


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Cognitive Drug Research (CDR) Computerized Assessment System Continuity of Attention [ Time Frame: 14 weeks ]
    Change from Baseline to End of Treatment in Continuity of Attention as measured by Cognitive Drug Research (CDR) Computerized Assessment System Continuity of Attention test

  2. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 14 weeks ]
    Assess the safety and tolerability of ANAVEX2-73 compared to placebo


Secondary Outcome Measures :
  1. MDS-UPDRS Part III Total Score (Motor Scores) [ Time Frame: 14 weeks ]
    Change from baseline to End of Treatment as measured by MDS-UPDRS Part III Total Score (Motor Scores)

  2. SDS-CL-25 [ Time Frame: 14 weeks ]
    Incidence of sleep disorders symptoms (SDS-CL-25)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of idiopathic Parkinson's disease (PD) consistent with the UK Parkinson's Disease Society Brain Bank diagnostic criteria.
  • Diagnosis of probable PD dementia (PDD) according to the Movement Disorder Society Task Force clinical diagnostic criteria.
  • Montreal Cognitive Assessment (MoCA) score of 13 to 23, inclusive, at Screening.
  • Male or female and aged ≥ 50 years.
  • Caregivers and subjects (or legal representative) must understand and have signed approved informed consent.
  • Caregivers and subjects (or legal representative) must be able to understand study requirements and be willing to follow instructions.
  • Stable regimen of anti-Parkinson's disease medications (including levodopa, dopamine agonists, MAO-B inhibitors, or the COMT inhibitor entacapone), which has been stable for at least 4 weeks prior to Baseline.
  • Treatment with cholinesterase inhibitor (rivastigmine, donepezil and galantamine (Exelon®, Aricept®, or Reminyl®) will be permitted, provided the dose has been stable for a minimum of 8 weeks prior to randomization.
  • Subjects with history of depression on antidepressant medications will be allowed if depression is controlled and they have been on a stable daily dose of the antidepressant for ≥8 weeks before Baseline.

  • Contraception:

    • Women of childbearing potential must use an acceptable method of contraception starting 4 weeks prior to study drug administration and for a minimum of 4 weeks after study completion. Otherwise, women must be postmenopausal (at least one year absence of vaginal bleeding or spotting) as confirmed by FSH greater than or equal to 40 mIU/mL or 40 IU/L or be surgically sterile.
    • Men with a potentially fertile partner must have had a vasectomy or be willing to use an acceptable method of contraception for the duration of the study and for 3 months after study drug discontinuation.

Exclusion Criteria:

  • History of any significant neurologic or psychiatric disorder other than PD that can contribute to cognitive impairment.
  • Any other condition or clinically significant abnormal findings like severe co-morbidities e.g. history of stroke, poor kidney or liver function on the physical or neurological examination, medical and psychiatric history, at screening or at baseline that, in the opinion of the Investigator, would make the subject unsuitable for the study.

  • Potential symptomatic causes of cognitive impairment including but not limited to

    1. abnormal thyroid function test at screening (TSH)
    2. abnormal B12 level at screening
    3. MRI findings (by history) pointing to a potential symptomatic cause of cognitive dysfunction, including significant vascular changes, or communicating hydrocephalus.
  • Treatment with memantine or amantadine. If appropriate the drugs can be discontinued for a minimum of 4 weeks prior to randomization.
  • Use of over the counter (OTC) or prescription medication for sleep on 2 or more occasions per week (less than that is allowed).
  • History of depression as measured by Beck Depression Inventory score >17 at screening.
  • Treatment with any other investigational drug or device within 4 weeks prior to screening.
  • Smoking > 1 pack of cigarettes per day (as assessed for the 4 weeks prior to screening).
  • Women who are pregnant or lactating.
  • Known allergy or sensitivity to ANAVEX2-73 or any of its components.
  • Suicidal ideation on the Columbia Suicide Severity Rating Scale (C-SSRS) of type 4 or type 5, or any suicidal behavior, in the past 6 months. Type 4 indicates active suicidal ideation with some intent to act, without a specific plan. Type 5 indicates active suicidal ideation with a specific plan and intent.
  • Use of centrally acting anticholinergic drugs during the 4 weeks before randomization.
  • Medications used for overactive bladder will be allowed provided that the regimen has been stable 4 weeks prior to randomization.
  • Treatment with any dopamine receptor blocking medications with the exception of low dose quetiapine (≤50 mg/day). Pimavanserin (≤34 mg/day) will be allowed.
  • History of neurosurgical intervention (e.g., deep brain stimulation) for PD.
  • Unpredictable motor fluctuations that would interfere with administering cognitive assessments in the ON state.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03774459


Locations
Show Show 25 study locations
Sponsors and Collaborators
Anavex Life Sciences Corp.
Anavex Germany GmbH
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Anavex Life Sciences Corp.
ClinicalTrials.gov Identifier: NCT03774459    
Other Study ID Numbers: ANAVEX2-73-PDD-001
First Posted: December 13, 2018    Key Record Dates
Last Update Posted: October 22, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Dementia
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
 Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders